Clinical trial
Multicentre Phase I/IIa Study of Infusion of Autologous Peripheral Blood T Lymphocytes Expanded and Genetically Modified Using Sleeping Beauty Family Transposons to Express a Chimeric Antigenic Receptor With Anti-CD19 Specificity Conjugated to the 4-1BB Co-stimulatory Region and CD3z and huEGFRt Signal Transmission (TranspoCART19) in Patients With Relapsed or Refractory B-cell Lymphoma
NCT06378190 is registered in ClinicalTrials.gov with Instituto de Investigación Biomédica de Salamanca as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Multicentre Phase I/IIa Study of Infusion of Autologous Peripheral Blood T Lymphocytes Expanded and Genetically Modified Using Sleeping Beauty Family Transposons to Express a Chimeric Antigenic Receptor With Anti-CD19 Specificity Conjugated to the 4-1BB Co-stimulatory Region and CD3z and huEGFRt Signal Transmission (TranspoCART19) in Patients With Relapsed or Refractory B-cell Lymphoma
- Lead sponsor
- Instituto de Investigación Biomédica de Salamanca
- Phase
- Phase 1/2
- Overall status
- Recruiting
- Start date
- March 11, 2024
- Completion date
- July 31, 2030
- Enrollment
- 27 (estimated)
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.
b-cell lymphoma recurrent, refractory b-cell lymphoma